Patients taking immunosuppressive and hepatitis B antiviral drugs after living donor liver transplant had lower antibody response to COVID-19 vaccination.

Bernaudin discussed the Drepagreffe-1 and 2 studies and improvements seen over 10 years of follow-up.

In the final segment of this episode, the discussion focuses on next steps for the PARASOL Initiative and its potential to transform FSGS drug development.

In part 3 of 4 from this episode, the discussion focuses on establishing surrogate endpoints for clinical trials in focal segmental glomerulosclerosis.

In part 2 of 4 from this episode, the discussion focuses on the groundbreaking work of the RADAR Registry and the PARASOL Initiative.

In part 1 of 4 from this episode, the discussion focuses on the backgrounds of guests Laura Mariani, MD, MS, and Daniel Gale, PhD, MB BChir.

This 4-part episode focuses on the PARASOL Initiative and the landscape of focal segmental glomerulosclerosis treatment.

This analysis involved assessing rates of lifetime as well as prior 12-month treatment use for AUD, in addition to demographic and clinical characteristics linked to AUD treatment.

Panelists discuss how antihypertensive treatment encompasses multiple drug classes with distinct mechanisms of action, alongside lifestyle modifications such as dietary changes and exercise, providing a comprehensive approach to blood pressure management.

Panelists discuss how antihypertensive treatment encompasses multiple drug classes with distinct mechanisms of action, alongside lifestyle modifications such as dietary changes and exercise, providing a comprehensive approach to blood pressure management.

The panel of experts examine the long-term data for the recently FDA-approved PPAR-δ agonist elafibranor in the treatment of primary biliary cholangitis (PBC), comparing its clinical findings with those of seladelpar, and explores how to choose the right peroxisome proliferator-activated receptor (PPAR) agonist and assess treatment effectiveness.

A new study identifies sex differences in MASLD adverse events, such as females having a greater risk of developing cirrhosis and males having a greater risk of non-liver cancers.

The panel of experts discuss the role of effectively treating pruritus, a common and debilitating symptom in over 80% of patients with cholestatic liver diseases like primary biliary cholangitis (PBC), and its importance in the long-term management of the disease.

The inflammation-based scoring system provides the first tool for predicting long-term mortality in hepatitis B-related acute on chronic liver failure.

Real-world clinical data from the Adelphi PNH II Disease Specific Programme were reported at ASH 2024.

The FDA-approved Scanly, a home-based OCT device, revolutionizes nAMD care by empowering patients with self-monitoring and enhancing personalized treatment.

Danicopan add-on therapy demonstrated more favorable safety in the ALPHA trial than pegcetacoplan did in the PEGASUS trial in a new analysis.

Investigators looked at the effects of the exposome among patients with atopic dermatitis in order to better understand the influence of such elements as obesity and microorganisms.

A study found only 38% of patients in the large US academic health system screened for depression received antidepressants or mental health referrals.

Hypovolaemic phlebotomy reduced perioperative blood transfusion and improved operative conditions versus usual care in patients undergoing liver resection.

Navigating the long road of Long COVID requires more than just recovery from an infection, it demands specialized, multifaceted care to address persistent and often invisible neurological symptoms.

These 52-week data highlight bimekizumab’s efficacy in the scalp, nail, and genital region for psoriasis, along with Dermatology Life Quality Index (DLQI) improvements.

Vivek Kaul, MD, discusses how primary care providers can effectively communicate the importance of colorectal cancer screening and guide patients in selecting the most suitable option, and the significant role of patient preferences and adherence in this decision-making process, while also addressing future innovations in screening methods.

A recent study found that loneliness among adults aged 50 – 80 increased from 2018 to 2022 and dropped in 2023 and 2024.

Mayo explains current shortcomings of pruritus care in PBC and what the additions of elafibranor, seladelpar, and other agents in development may offer.